Prevalence and Correlates of Self-reported Nonadherence With Eye Drop Treatment

Abstract

The prevalence of self-reported nonadherence was congruent with literature. The patients visiting their ophthalmologists at least every 3 months have a lower risk of nonadherence. Ophthalmologist report is an insensitive method for detecting nonadherence.

Difluprednate 0.05% Versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: A Phase III, Multicenter, Randomized Study

“…Ophthalmic medications with a less frequent dosing requirement have been associated with better compliance as demonstrated in therapies for glaucoma 12,22 or allergic conjunctivitis. 23 Similar benefits can be expected with difluprednate 0.05%, which requires dosing at a substantially lower frequency than prednisolone acetate 1%.…”

“…However, prednisolone acetate 1% usually demands frequent dosing, particularly for severe cases, in which increased administration frequency is required. 1,11 As demonstrated with glaucoma medications, frequent dosing may increase the risk of noncompliance, 12 which may negatively affect the achievement of therapeutic goals. 1 For patients who fail to respond to topical treatment, increased dosage of the topical treatment, periocular (subtenon) or intraocular (intravitreal) corticosteroid injections (triamcinolone), intraocular corticosteroid depot treatment (fluocinolone), or oral corticosteroid therapy may be necessary.…”

Induced Pluripotent Stem Cells Restore Function in a Human Cell Loss Model of Open-Angle Glaucoma

“…In both cases, since a key function of aqueous humor is to bathe and nourish the avascular lens, cornea, and TM, reduced aqueous humor circulation through the conventional TM outflow pathway will further exacerbate the condition of the diseased tissue [1,3,7]. In addition, therapeutic compliance remains a very serious issue with published estimates of 27.8%, 50%, or even 75% noncompliance [45][46][47][48]. This is primarily due to side effects and the requirement for daily self-application of eye drops.…”

Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies

“…[20][21][22][23][24] In other ophthalmic indications, less frequent dosing of topical ophthalmic medications has been reported to be one of the factors associated with better treatment compliance, which may provide an advantage for difluprednate with a four times daily initial therapy label. 9,25 In addition, difluprednate has been reported to have better dose uniformity than branded and generic prednisolone acetate suspensions under various storage conditions. 26 Moreover, the preservative system used in difluprednate emulsion (sorbic acid) may cause only minimal damage or irritation to the ocular surface, particularly in patients with existing ocular surface disease, unlike benzalkonium chloride (BAK) preservative.…”

“…5,7,8 Frequent dosing of prednisolone acetate 1% (≥8 times daily) is generally necessary to ensure a rapid improvement, and frequent dosing in general may increase the risk of noncompliance. 9 Difluprednate is a novel difluorinated prednisolone derivative with high potency and a favorable safety profile. [10][11][12] Difluprednate 0.05% 4 times daily (QID) is approved for the treatment of EAU in the United States.…”